Monal Sanghvi
-
Why Supreme Court's Anger Against Private Healthcare Costs Is Justified
Rates charged by private hospitals can be as much as 10 times of what is prescribed under the CGHS.
-
Why Supreme Court's Anger Against Private Healthcare Costs Is Justified
Rates charged by private hospitals can be as much as 10 times of what is prescribed under the CGHS.
-
Specialisation Key Theme For Pharma, Healthcare: Quadria Capital's Amit Varma
Varma prefers hospitals catering to a single specialty over multi-specialties.
-
Sun Pharma's Dilip Shanghvi Aims To Raise R&D Spend To $1 Billion — NDTV Profit Exclusive
Dilip Shanghvi aspires to increase Sun Pharma's research and development spend to a billion dollars in the next three to five years.
-
Government To Subsidise Pharma Quality Compliance, Says Deputy Drugs Controller—NDTV Profit Exclusive
The DOP is planning subsidies to ensure quality compliance, and official announcements will be made soon, he said.
-
Takeda To Manufacture 50% Of Its Dengue Vaccines In India
Takeda will partner with Biological E to manufacture the vaccine.
-
Takeda To Manufacture 50% Of Its Dengue Vaccines In India
Takeda will partner with Biological E to manufacture the vaccine.
-
New Pharma Guidelines To Make Drugs Quality At Par With Global Standards: IDMA's SM Mudda
The IDMA will offer consultations to help organisations cope with the new standards, he says.
-
Data Integrity A Persistent Issue With Indian Pharma Plants, Says U.S. FDA's Sarah McMullen
While plant inspections have gone up two-and-a-half times post Covid, official action is suggested in fewer instances.
-
Data Integrity A Persistent Issue With Indian Pharma Plants, Says U.S. FDA's Sarah McMullen
While plant inspections have gone up two-and-a-half times post Covid, official action is suggested in fewer instances.
-
GPT Healthcare IPO: All You Need To Know
The company plans to raise Rs 525 crore through combination of fresh issue of Rs 40 crore and an offer for sale of 2.61 crore shares, which would be around Rs 485 crore. The issue opens on Feb. 22.
-
Glenmark Pharma Q3 Results: Reports Net Loss Of Rs 331 Crore
The Mumbai-based bulk and generic drugmaker reported a net loss of Rs 331 crore, as compared with a net profit of Rs 291 crore over the same period last year.
-
Cipla Expects To Sustain 24% Ebitda Margin, Says Management
The company is looking to organically expand in India by increasing focus on chronic prescription.
-
Cipla Expects To Sustain 24% Ebitda Margin, Says Management
The company is looking to organically expand in India by increasing focus on chronic prescription.
-
Gland Pharma Q3 Results: Profit Falls, Misses Estimates
The net profit of the Hyderabad-based generic injectable manufacturer fell 17% year-on-year to Rs 192 crore in the three months through December.
